Tat-NR2B9c(TFA)是由20个氨基酸组成的多肽，为PSD-95的抑制剂，对PSD-95d2和PSD-95d1的EC50值分别为6.7nM和670nM。Tat-NR2B9c同时可降低NMDA诱导的p38的活化，具有神经保护作用。
| Cas No. | 1834571-04-8 |
| 别名 | Tat-NR2Bct TFA; NA-1 TFA |
| Canonical SMILES | OC(C(F)(F)F)=O.[YGRKKRRQRRRKLSSIESDV] |
| 分子式 | C107H189F3N42O32 |
| 分子量 | 2632.9 |
| 溶解度 | Water : ≥ 50 mg/mL (18.99 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Tat-NR2B9c (TFA) is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1[1]. Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy[2].
EC50: 6.7 nM (PSD-95d2), 670 nM (PSD-95d1)[1]p38[2] [1]. Cui H, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007 Sep 12;27(37):9901-15.
[2]. Fan J, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012 Mar;45(3):999-1009. |
